This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FOMX Menlo Therapeutics (FOMX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Menlo Therapeutics Stock (NASDAQ:FOMX) 30 days 90 days 365 days Advanced Chart Get Menlo Therapeutics alerts:Sign Up Key Stats Today's Range$2.99▼$2.9950-Day Range$2.99▼$2.9952-Week Range$1.97▼$4.84VolumeN/AAverage Volume518,350 shsMarket Capitalization$184.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel. Read More Receive FOMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Menlo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FOMX Stock News HeadlinesMenlo Ventures in Market for Next Set of Funds With AI FocusJune 28, 2025 | wsj.comPatient advocate startup Solace is set to be valued at over $300 million in new funding round from Menlo VenturesMarch 26, 2025 | businessinsider.comThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains. | Weiss Ratings (Ad)How to Watch Local FOX Stations Without CableNovember 13, 2024 | msn.comMichael J. Fox Foundation taps Palo Alto AI firmOctober 29, 2024 | bizjournals.comMenlo Club Unboxing & Review ¦ Is It Worth It¿October 18, 2024 | msn.comSelonterra Awarded Second Grant from The Michael J. Fox Foundation for Parkinson's ResearchOctober 9, 2024 | msn.comMenlo Security Exceeds $100M ARR, Delivers Secure Enterprise Browser Market LeadershipOctober 1, 2024 | tmcnet.comSee More Headlines FOMX Stock Analysis - Frequently Asked Questions How were Menlo Therapeutics' earnings last quarter? Menlo Therapeutics Inc. (NASDAQ:FOMX) posted its earnings results on Monday, November, 11th. The specialty pharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.07. What other stocks do shareholders of Menlo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Menlo Therapeutics investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Bristol Myers Squibb (BMY), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings11/11/2019Today8/01/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & Botanicals Sub-IndustryN/A Current SymbolNASDAQ:FOMX CIK1606645 Webwww.foamix.com Phone972-8931-6233FaxN/AEmployees80Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-100.58% Return on Assets-81.39% Debt Debt-to-Equity Ratio0.24 Current Ratio5.72 Quick Ratio5.72 Sales & Book Value Annual Sales$3.60 million Price / Sales51.15 Cash FlowN/A Price / Cash FlowN/A Book Value$1.70 per share Price / Book1.76Miscellaneous Outstanding Shares61,580,000Free FloatN/AMarket Cap$184.12 million OptionableOptionable Beta1.66 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:FOMX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Menlo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Menlo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.